Find Funding Opportunities

Returning 185 results

Serious Adverse Drug Reaction Research (R21)

PAR
Thursday, May 19, 2016
Sunday, September 8, 2019
R21
PAR-16-274

Funding Opportunity Purpose

This Funding Opportunity Announcement is to support research grants that will advance the state of knowledge of serious adverse drug reactions. Applications across the spectrum of research are encouraged.

Dissemination and Implementation Research in Health (R03)

PAR
Tuesday, May 10, 2016
Clinical Research
Wednesday, May 8, 2019
R03
PAR-16-237
Salina Waddy, M.D.

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures, and strategies to disseminate and implement evidence-based health behavior change interventions, evidence-based prevention, early detection, diagnostic, treatment and management, and quality of life improvement services into public health, clinical practice, and community settings.

Neural Regulation of Cancer (R21)

PAR
Monday, May 9, 2016
Friday, June 28, 2019
R21
PAR-16-246

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

Tools for Cell Line Identification (R43/R44)

PA
Friday, April 15, 2016
Saturday, April 6, 2019
R43/R44
PA-16-186

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) is intended to address the problem of misidentified cell lines. Many advances in biomedical science have arisen from studies of cultured cell lines, which are widely used for basic research on cell function, as models for disease, and for drug screening. However, cell cultures are prone to contamination by foreign cells, which may rapidly displace the original cells. The identity of cultured cells should be routinely verified, but a majority of laboratories do not monitor the identity of their cell lines, and many cell lines are misidentified. The costs, effort and time required to confirm the identity of cell lines has been a barrier to adoption of cell line identification as a routine quality control measure. This FOA will support SBIR projects to improve existing technologies, and/or develop novel, reliable, and cost effective tools that will make it easier for researchers to confirm the identity and/or sex of the cells that they use in their work. Applications for support of research and development of particular types of complex technologies that require funding levels and durations beyond those reflected in standard SBIR guidelines are encouraged, as are multi-PD/PI applications, including multi-PD/PI applications that arise from academic-industrial partnerships.

NIH Exploratory/Developmental Research Grant Program (Parent R21)

PA
Thursday, March 31, 2016
Wednesday, May 8, 2019
R21
PA-16-161

Funding Opportunity Purpose

The National Institutes of Health (NIH) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in categorical program areas. The R21 activity code is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Pages